Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Outlines “Expedited” Review For Breakthrough Therapies; “Hyper-Fast” Reviews, Beyond Oncology

This article was originally published in RPM Report

Executive Summary

Oncology drug sponsors have gotten used to a “faster-than-Priority” timeline for breakthrough products. Now, FDA is outlining a formal process for its reviewers to use for any “Breakthrough” designated therapy with life-saving potential.


Related Content

Breakthrough Nears 50 Approvals: Process Improving, But “Gray Areas” Persist
Oncology PROs: Limited Use Due To Small Trials, Fast Drug Development
FDA Responds to Nagging Questions About “Lagging” Drug Review Divisions
FDA ‘Expedited Review’ Would Shave Off Additional Month For Some ‘Breakthrough’ Products
‘Breakthrough’ Drugs Get ‘Road-MaPP’ – Complete With Communication Timetable
FDA’s “Breakthrough” Evolves: What’s Next For The Popular Program?
Cancer Therapies: The Breakthrough Era
Skipping the Advisory Committee, but Getting the Advice


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts